Supplementary Material for: The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives

<p>Aspirin and other non-steroidal anti-inflammatory</p> <p>drugs (NSAIDs) have received considerable interest as</p> <p>potential chemopreventive agents. The aim of this review</p> <p>is to summarize the accumulated knowledge on</p> <p>the effect of NSAIDs on breast cancer incidence and</p> <p>natural history, and the underlying pathophysiology.</p> <p>NSAIDs mainly block inflammation by inhibiting cyclooxygenase</p> <p>enzymes, leading to lower prostaglandin</p> <p>synthesis. The latter has been reported to affect breast</p> <p>cancer risk through hormonal and inflammation-related</p> <p>pathways. Intensity, dose, frequency, duration,</p> <p>and timing of administration may also be significant.</p> <p>There is currently enough evidence to support a role of</p> <p>NSAIDs in breast cancer prevention and relapse, which</p> <p>deserves further large-scale experimental and clinical</p> <p>investigation.</p>